Mira Pharmaceuticals Inc
MIRA Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company's pipeline includes oral drug candidates designed to address significant unmet medical needs in neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline. It holds exclusive license rights in the United States, Canada and Mexico for Ketamir-2 and MIRA-55, two novel drug candidates designed to address unmet medical needs in neuropathic and inflammatory pain, as well as neuropsychiatric and neurocognitive disorders. Its pipeline also includes SKNY-1, a next-generation oral therapy candidate for obesity and smoking cessation. Ketamir-2 is a patent-pending oral ketamine analog evaluated for the treatment of diabetic neuropathy and is in an ongoing Phase I clinical trial.
Stock Performance Snapshot
Analyst Rating
Analysts highly recommend buying Mira Pharmaceuticals' stock with a target price of $16.5, indicating significant upside.
Financial Health
Mira Pharmaceuticals has a modest book value and cash flow per share, indicating stable performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring MIRA
Mind & Spirit
Invest in companies transforming mental healthcare through innovative treatments and technologies. These carefully selected stocks represent leaders in psychedelic therapeutics, telehealth platforms, and neurological treatments addressing the growing global demand for mental wellness solutions.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical Milestones Ahead
Trial readouts and regulatory progress can drive significant share moves, though outcomes are uncertain and delays common.
Funding & Dilution
Small biotechs frequently need to raise capital; fundraising terms can dilute existing shareholders and affect timelines.
Partnering Potential
Licensing or collaboration deals may validate programmes and reduce execution risk, but depend on data and negotiation outcomes.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
